US-based healthcare software developer WellDoc has achieved a first close of its $22m series B round co-led by electronics conglomerate Samsung and healthcare company Merck.
Samsung participated through its corporate venturing unit Samsung Ventures, while Merck contributed funds through its investment vehicle Global Health Innovation Fund.
Adage Capital Management, Excel Venture Management, Alexandria Venture Investments and Hudson River Capital Partners also took part in the round.
Founded in 2005, WellDoc is developing software dubbed BlueStar that helps patients suffering from…